Sanford Burnham Prebys Medical Discovery Institute

The Salk Institute for Biological Studies

Yale University

Sanford-burnham Medical Research Institute

Mitchell Dennis Vamos

Nicholas David Peter Cosford

Douglas J Sheffler

Benjamin Turk

Reuben J Shaw

Dhanya Raveendra Panickar

Matthew Chun

Nicholas Cosford

Daniel F Egan

John A T Young

Sumit K Chanda

John M Marlett

Peter Teriete

Arturo Diaz

Lars Pache

Nicholas David Cosford

John At Young

John AT Young

Douglas James Sheffler

John Marlett

Provided herein are compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

Inhibitor of apoptosis protein (IAP) antagonists

Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV).

Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy

In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

ULK1 inhibitors and methods using same

Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV). Described herein is the use of IAP antagonists in the treatment of human immunodeficiency virus (HIV) in a mammal, alone or in combination with other therapeutic agents used in HIV therapy. In one aspect, provided herein is a method of treating human immunodeficiency virus (HIV) in an individual in need thereof comprising administering a therapeutically effective amount of at least one inhibitor of apoptosis proteins (IAP) antagonist.

Provided herein are compounds that modulate the activity of inhibitor of apoptosis proteins (IAPB), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

Growing community of inventors

La Jolla, CA, United States of America

Mitchell Dennis Vamos